Federal Register Reported FDA Announcing Revocation Of EUAs Issued To Bio-Rad Laboratories For The Bio-Rad Sars-Cov-2 DDPCR Kit

Federal Register Reported FDA Announcing Revocation Of EUAs Issued To Bio-Rad Laboratories For The Bio-Rad Sars-Cov-2 DDPCR Kit

BenzingaMay 17 06:04

Bio-Rad Laboratories, Inc. (NYSE:BIO) Just Reported, And Analysts Assigned A US$394 Price Target

Last week saw the newest quarterly earnings release from Bio-Rad Laboratories, Inc. (NYSE:BIO), an important milestone in the company's journey to build a stronger business. The analysts typi

Simply Wall StMay 12 07:19

Bio-Rad Laboratories | 10-Q: Quarterly report

Futu NewsMay 8 15:38 · Announcements

UBS Adjusts Price Target on Bio-Rad Laboratories to $385 From $420, Maintains Buy Rating

Bio-Rad Laboratories (BIO) has an average outperform rating and price target range of $365 to $441, according to analysts polled by Capital IQ. Price: 271.46, Change: -8.45, Percent Change: -3.02

MT NewswiresMay 8 09:19

Bio-Rad Laboratories Price Target Cut to $385.00/Share From $420.00 by UBS

Bio-Rad Laboratories Price Target Cut to $385.00/Share From $420.00 by UBS

Dow JonesMay 8 08:37

Bio-Rad Laboratories Is Maintained at Buy by UBS

Bio-Rad Laboratories Is Maintained at Buy by UBS

Dow JonesMay 8 08:37